Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

28 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

INDIRECT OPHTHALMOSCOPY (DAY 0) CRFs Roche FVF4170G Macular Edema NCT00473382

- 09/06/17 - 1 modulo, 3 itemgroups, 21 elementi, 1 linguaggio
Itemgroups: Patient administration, INDIRECT OPHTHALMOSCOPY (DAY 0), INDIRECT OPHTHALMOSCOPY (DAY 0)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (SCREENING) CRFs Roche FVF4170G Macular Edema NCT-Nummer: NCT00473382

- 08/06/17 - 1 modulo, 3 itemgroups, 45 elementi, 1 linguaggio
Itemgroups: Patient administration, INDIRECT OPHTHALMOSCOPY (SCREENING), INDIRECT OPHTHALMOSCOPY (SCREENING)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (DAY 0) CRFs Roche FVF4168G Macular Edema NCT00473330

- 08/06/17 - 1 modulo, 3 itemgroups, 21 elementi, 1 linguaggio
Itemgroups: Patient administration, INDIRECT OPHTHALMOSCOPY (DAY 0), INDIRECT OPHTHALMOSCOPY (DAY 0)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

INDIRECT OPHTHALMOSCOPY (SCREENING) CRFs Roche FVF4168G Macular Edema NCT00473330

- 08/06/17 - 1 modulo, 3 itemgroups, 45 elementi, 1 linguaggio
Itemgroups: Patient administration, INDIRECT OPHTHALMOSCOPY (SCREENING), INDIRECT OPHTHALMOSCOPY (SCREENING)
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial